Literature DB >> 11682462

Cell cycle attenuation by p120E4F is accompanied by increased mitotic dysfunction.

R J Rooney1.   

Abstract

In addition to their well-established roles at the G1-S checkpoint, recent reports support a role for universal cyclin-dependent kinase (CDK) inhibitors in the control of G2-M and suggest that their induction may stimulate the occurrence of endomitosis or polyploidy in a number of physiological settings. In this report, the stable expression of the p120E4F transcription factor, which attenuates G1-S progression by elevating p21WAF1 and p27KIP1 protein levels, was shown to also interfere with the regulation of G2-M and cytokinesis. Exponentially growing cultures of p120E4F-expressing fibroblast cell lines had reduced levels of CDC2 kinase activity, elevated levels of Cyclin B1 protein, and continuously generated a subpopulation of tetraploid cells and elevated numbers of multinucleated cells. Coexpression of activated Ras, which stimulates Cyclin D1 expression and G1-S-specific cyclin-CDK kinase activities, alleviated these effects without reducing p21WAF1 or p27KIP1 protein levels; p120E4F/ras-expressing cell lines contained reduced levels of Cyclin B1 protein, a restoration of Cyclin B-CDC2 kinase activity to control levels, and exhibited no increase of tetraploid or multinucleated cells. Interestingly, changes in the expression of Cyclin B1 and, to a lesser extent, CDC2 were primarily regulated by post-transcriptional mechanisms. The results indicate that mechanisms which moderately elevate CDK inhibitor levels can reduce CDC2 kinase activity to the point of impeding normal G2-M function and suggest that two molecular determinants commonly associated with the induction of polyploidy in a number of tissues, i.e., elevated levels of universal CDK inhibitors and sustained CDK2 kinase activity, may be solely sufficient to initiate endomitosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682462

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

1.  The E4F protein is required for mitotic progression during embryonic cell cycles.

Authors:  Laurent Le Cam; Matthieu Lacroix; Maria A Ciemerych; Claude Sardet; Piotr Sicinski
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

2.  E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cells.

Authors:  Jalila Chagraoui; Sherry L Niessen; Julie Lessard; Simon Girard; Philippe Coulombe; Martin Sauvageau; Sylvain Meloche; Guy Sauvageau
Journal:  Genes Dev       Date:  2006-08-01       Impact factor: 11.361

3.  E4F1, a novel estrogen-responsive gene in possible atheroprotection, revealed by microarray analysis.

Authors:  Yasuhiro Nakamura; Katsuhide Igarashi; Takashi Suzuki; Jun Kanno; Tohru Inoue; Chika Tazawa; Masayuki Saruta; Tomoko Ando; Noriko Moriyama; Toru Furukawa; Masao Ono; Takuya Moriya; Kiyoshi Ito; Haruo Saito; Tadashi Ishibashi; Shoki Takahashi; Shogo Yamada; Hironobu Sasano
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma.

Authors:  Michael J Schwerer; Jörg Hemmer; Klaus Kraft; Heinz Maier; Peter Möller; Thomas F E Barth
Journal:  Virchows Arch       Date:  2003-05-15       Impact factor: 4.064

5.  Multiple domains in the 50 kDa form of E4F1 regulate promoter-specific repression and E1A trans-activation.

Authors:  Robert J Rooney
Journal:  Gene       Date:  2020-06-11       Impact factor: 3.688

6.  Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2.

Authors:  Michela A Tessari; Monica Gostissa; Sandro Altamura; Riccardo Sgarra; Alessandra Rustighi; Clio Salvagno; Giuseppina Caretti; Carol Imbriano; Roberto Mantovani; Giannino Del Sal; Vincenzo Giancotti; Guidalberto Manfioletti
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

7.  E4F1 deficiency results in oxidative stress-mediated cell death of leukemic cells.

Authors:  Elodie Hatchi; Genevieve Rodier; Matthieu Lacroix; Julie Caramel; Olivier Kirsh; Chantal Jacquet; Emilie Schrepfer; Sylviane Lagarrigue; Laetitia Karine Linares; Gwendaline Lledo; Sylvie Tondeur; Pierre Dubus; Claude Sardet; Laurent Le Cam
Journal:  J Exp Med       Date:  2011-06-27       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.